SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06155604

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06155604
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06155604. Randomized; double masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Condition
Lupus Nephritis
Condition
Chronic Kidney Diseases
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Drug)
Standard maintenance therapy
Lead sponsor
The University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct06155604
Content hash
00a12c2c1aa23402ace5efdf289f9e6ea84cee3dc8aca1d8fa5cdd0574342f49